Caffeine Market Global Report 2024, Featuring CSPC Innovation, BASF, Shandong Xinhua, SJZ No.4 Pharmaceutical, Jilin Shulan Synthetic, Aarti Industries, Ahinsha Chemicals and Anhui Redstar

Yahoo FinanceNov 15 04:07 ET

Shandong Xinhua Pharmaceutical Announces December EGM

TipRanksNov 13 04:09 ET

The new policy of prepayment of medical insurance fund has been released, and the pharmaceutical sector has ushered in a sharp rise. Experts believe it may be a way for medical institutions to release funding pressure.

On the 11th, the "Notice on Prepayment of Medical Insurance Fund" was issued, requiring the unified and improved basic medical insurance fund prepayment system at the national level. Experts believe that the prepayment system can effectively alleviate the problem of pharmaceutical industry debt, accelerate the turnover of funds for pharmaceutical companies. The medical sector showed a significant upward trend today, with listed companies attributing the rise to investor sentiment.

cls.cnNov 12 02:44 ET

Multiple bullish factors boost pharmaceutical Hong Kong stocks. Institutions say they still face this risk in the short term.

①What are the policy measures to support the field of innovative drugs? ②What unfavorable effects on domestic pharmaceutical stocks might Trump's election bring about?

cls.cnNov 11 21:59 ET

shandong xinhua pharmaceutical (00719.HK) subsidiary febuxostat tablets obtained drug registration certificate suitable for long-term treatment of hyperuricemia with symptoms of gout.

GeLongHui November 11th | Shandong Xinhua Pharmaceutical (00719.HK) announced that recently, its wholly-owned subsidiary Shandong Zibo Xinda Pharmaceutical Co., Ltd. (referred to as "Xinda Pharmaceutical") has received the National Medical Products Administration's approval to issue the Drug Registration Certificate for Nifbuseltam Tablets (referred to as "this product"), approving the application for marketing authorization of this product. In June 2023, Xinda Pharmaceutical submitted the application materials for the registration and marketing authorization of Nifbuseltam tablets to the Center for Drug Evaluation of the National Medical Products Administration and was accepted. In November 2024, it obtained the Drug Registration Certificate, and the evaluation conclusion was: batch.

Gelonghui FinanceNov 11 03:55 ET

Express News | Shandong Xinhua Pharmaceutical - Febuxostat Tablets Obtained Drug Registration Certificate From Nmpa

ReutersNov 11 03:52 ET